Verrica Pharmaceuticals (VRCA) Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Verrica Pharmaceuticals (VRCA) Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Pa

August 14, 2024 7:30 AM EDT

VP-315 was well tolerated with no reported treatment-related serious adverse events

All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86%

Approximately 51% of lesions treated in Part 2 achieved complete histological clearance

Patients with residual tumor on average achieved an approximate 71% reduction in tumor size

~3.6 million basal cell carcinomas diagnosed in the U.S. each year, which is expected to continue to grow due to aging US population,... More